Neuroendocrine differentiation in prostate cancer: An unrecognized and therapy resistant phenotype;Neuroendokrine differenzierung im prostatakarzinom: Ein marker für die androgen- und strahlenresistenz

Pathologe

Volumn 26, Issue 6, 2005, Pages 453-460

  Bonkhoff, H ^a,c   Fixemer, T ^b  

^a Institut fur Pathologie   (Germany)

^b FRAUNHOFER INSTITUTE FOR BIOMEDICAL ENGINEERING   (Germany)

^c NONE   (Germany)

Author keywords

Androgen insensitivity; Chromogranin A; Neuroendocrine differentiation; Prostate cancer; Radiation therapy

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL POPULATION; CELL PROLIFERATION; CYTOPATHOLOGY; DRUG CYTOTOXICITY; HORMONE INHIBITION; HORMONE RESISTANCE; HORMONE SYNTHESIS; HUMAN; MITOSIS INHIBITION; NEUROENDOCRINE SYSTEM; PHENOTYPE; PROSTATE CARCINOMA; REVIEW; TISSUE SECTION; TUMOR CELL;

ADENOCARCINOMA; APOPTOSIS; CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; GROWTH SUBSTANCES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 27744431970     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-005-0791-0     Document Type: Review

References (30)

1. Ahel MZ, Kovacic K, Tarle M (2001) Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Anticancer Res 21:1363-1366
2. Berruti A, Dogliotti L, Mosca A et al. (2000) Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88:2590-2597
3. Bonkhoff H (1998) Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 8:18-22
4. Bonkhoff H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Arch Oncol Suppl 2:141-144
5. Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28:98-106
6. Bonkhoff H, Remberger K (1998) Morphogenetic concepts of normal and abnormal growth of the human prostate. Virchows Arch 433, 195-202
7. Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423:291-294
8. Bonkhoff H, Stein U, Remberger K (1994 a) Multi-directional differentiation in the normal, hyperplastic and neoplastic human prostate. Simultaneous demonstration of cell specific epithelial markers. Hum Pathol 25:42-46
9. Bonkhoff H, Stein U, Remberger K (1994 b) The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118
10. Bonkhoff H, Wernert N, Dhom G, Remberger K (1991) Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate 18:91-98
11. Bonkhoff H, Stein U, Remberger K (1995) Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 26:167-170
12. Bonkhoff H, Stein U, Aumüller G, Remberger K (1996) Differenzial expression of 5 α-reductase isoenzymes in the human prostate and prostatic carcinoma. Prostate 29:261-267
13. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MiB-1), and phenotype markers in routinely processed tissue sections. Virchows Arch 434:71-73
14. Bostwick DG, Grignon DJ, Hammond ME et al. (2000) Prognostic factors in prostate cancer. College of American Pathologists, Consensus Statement 1999. Arch Pathol Lab Med 124:995-1000
15. Chuang CK, Wu TL, Tsao KC, Liaso SK (2003) Elevated serum Chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc 102:480-485
16. Di Sant'Agnese PA, Cockett AT (1996) Neuroendocrine differentiation in prostatic malignancy. Cancer 78:357-361
17. Di Silverio F, Sciarra A (2003) Combiation therapy of ethinylestadiol and soamtostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer. J Urol 170:1812-1816
18. Fixemer T, Remberger K, Bonkhoff H (2002) Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53:118-123
19. Hvamstad T, Jordal A, Hekmat N et al. (2003) Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 44:215-221
20. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP (1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152:1-9
21. Lilleby W, Paus E, Skovlund E, Fossa SD (2001) Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 46:126-133
22. Sciarra A, Mariotti G, Gentile V et al. (2003 a) Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91:438-445
23. Sciarra A, Monti S, Gentile V et al. (2003 b) Variation in chromogranin A serum levels during intermittent vs. continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55:168-179
24. Sciarra A, Voria G, Monti S et al. (2005) Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 58:421-428
25. Tarle M (1999) Serum chromogranin A in monitoring metastatic prostate cancer patients. Anticancer Res 19:5663-5666
26. Tarle M, Ahel MZ, Kovacic K (2002) Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 22:2525-2529
27. Theodorescu D, Broder SR, Boyd JC et al. (1997) Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80:2109-2119
28. Weinstein MH, Partin AW, Veltri RW, Epstein JI (1996) Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 27:683-687
29. Wiegel T (2002) Prostatakarzinom. Onkologe Suppl 1:518-520
30. Zaky Ahel M, Kovacic K, Kraljic I, Tarle M (2001) Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 21:1475-1479